Jing Fu

Assistant Professor @Columbia Medical Center, focusing on multiple myeloma and AL Amyloidosis. Tweets are my own opinions.

[Suzanne Lentzsch, MD, PhD @SLentzsch]

One of the most rewarding and emotional moments of my career took place at #ASCO2026. In 2015, I started the first-in-human trial of 11-1F4 (now anselamimab), supported by a small FDA grant and @columbiacancer. At the time, the path forward was far from certain. We faced limited funding, strong competition from Prothena’s NEOD001 program, and considerable skepticism from industry given the rarity of AL amyloidosis and the fact that competing programs were already much further advanced in development.

Despite these challenges, we continued to move forward step by step. The phase 1 study demonstrated encouraging results, ultimately leading to the founding and funding of Caelum Biosciences in 2017 and the launch of the subsequent phase 2 and phase 3 studies. Those efforts were later advanced and completed through the commitment and resources of @AlexionCARES and @AstraZenecaUS.

@ASCO I had the privilege of chairing the session when the final phase 3 results where presented by Dr. Wechalekar, which demonstrated a significant overall survival benefit in patients with stage IIIA/IIIB κ AL amyloidosis🙌. Seeing a scientific concept evolve from an investigator-initiated first-in-human study into a positive phase 3 trial is extraordinarily rewarding.

This achievement reflects the dedication of countless patients, supporters🙏@MorieGertz, investigators, research staff, industry partners, and advocates who believed in this program over many years. It is also a powerful reminder of why we do translational research-to transform promising science into therapies that meaningfully improve patients' lives.

#ASCO2026 #ALAmyloidosis @Amyloidosis_ARC @Amyloidosisfdn @AmyloidosisSupp @ISA_Amyloidosis

[Jing Fu @JingFu_PhD]

@NBahlis @hollyleeYJ Congratulations 🎉🎊🎈

[Samer Al Hadidi, MD,MS,FACP @HadidiSamer]

#ASH25 #mmsm @ASH_hematology

Treatment Refinement in Multiple Myeloma

@SLentzsch

MM care evolution with the drug approvals over the years

[Suzanne Lentzsch, MD, PhD @SLentzsch]

#ASH25 Excellent presentation by @MSHughes_MD on our lambda specific AL amyloid mAb showing lambda specific amyloid resolution invited and in vivo @columbiacancer @Amyloiosisfdn @Amyloidosis_ARC @AmyloiosisSupp

[Samer Al Hadidi, MD,MS,FACP @HadidiSamer]

#ASH25 #mmsm @ASH_hematology

#ASHKudos @rajshekharucms for 2 oral presentations likely to change future of AL amyloidosis care

[Suzanne Lentzsch, MD, PhD @SLentzsch]

#ASH25 Isatuximab induces excellent response rate in MGRS in presented by @DivayaB @columbiacancer

[Raj Chakraborty @rajshekharucms]

⁦@DivayaB⁩ from ⁦@columbiacancer⁩ presenting safety and efficacy data of single-agent isatuximab in MGRS (PGNMID and C3GN). Renal response in 3/3 patients with C3GN!
#ASH25

[Suzanne Lentzsch, MD, PhD @SLentzsch]

#ASH25 High ORR 100% VGPR to Etentamig (BCMA bisp mAb) in RRAL #amyloidosis presented by @rajshekharucms

[Jing Fu @JingFu_PhD]

@LiliWangLab @cityofhope @columbiacancer Congratulations 🎉🎊🍾

[The International Society Of Amyloidosis @ISA_Amyloidosis]

Congratulations to lead author Vaishali Sanchorawala, MD and her co-authors on the publication of the ISA position paper ““A collaborative approach to amyloidosis and a multidisciplinary care framework” in Amyloid!

Check out the article: https://t.co/r8PBxAE3rr

@vsanchorawala

[Myeloma Society @Myeloma_Society]

Josefine Krüger, MD, IMS Riney CD Awardee, identified a previously unknown cereblon-independent mechanism of proteasomal degradation of IKZF1 (Ikaros) transcription factor, a key target of immunomodulatory drugs. @josi_kr #IMS25

[Myeloma Society @Myeloma_Society]

The IMS Leadership expressed their heartfelt gratitude to Rodger and Paula Riney, recognizing their steadfast generosity and unwavering commitment to the IMS and the global myeloma community. #IMS25

[Vincent Rajkumar @VincentRK]

Inspiring lecture by @Leif_Bergsagel @MayoClinic after receiving the Ken Anderson Award at #IMS25 @Myeloma_Society

Leif has made huge contributions to our understanding of the biology of the disease. Congrats Leif!

[Jing Fu @JingFu_PhD]

@josi_kr @Myeloma_Society Congratulations!! Really awesome work 👏👏

[Robert Z. Orlowski @Myeloma_Doc]

#Myeloma Paper of the Day: Germinal center kinase inhibition enhances iberdomide's anti-myeloma effects by promoting IKZF1 degradation via a CRBN-independent mechanism in both in vitro and in vivo models: https://t.co/FZaRUIngTT. #mmsm @SLentzsch @DivayaB

[Suzanne Lentzsch, MD, PhD @SLentzsch]

#IMS25 New concept of anti-amyloid strategy using CAR-Macrophages presented by @JingFu_PhD from our lab @columbiacancer 👍🏻

[Suzanne Lentzsch, MD, PhD @SLentzsch]

#IMS25
Outstanding presentation by @josi_kr from our lab @columbiacancer on RAS mutated Myeloma. What a wonderful opportunity to thank Paula and Roger Riney directly for their generous support and making our research possible @Myeloma_Society #mmsm

[Raj Chakraborty @rajshekharucms]

Congrats @SLentzsch!!

[Faiz Anwer MD @FaizAnwerMD1]

Our new paper out now in Blood Reviews, on a potentially groundbreaking therapy for AL Amyloidosis, CAEL-101

https://t.co/XjaJfMJZiJ

[Suzanne Lentzsch, MD, PhD @SLentzsch]

‼️‼️Our translational laboratory https://t.co/wpNiIYV7cj @columbiacancer would be happy to host young scientists for projects on myeloma bone disease or development of targeted treatments for plasma cell dyscrasia including AL Amyloidosis @columbiacancer @Myeloma_Society #mmsm